Enovis (NYSE:ENOV) Issues Quarterly Earnings Results

Enovis (NYSE:ENOV - Get Free Report) issued its earnings results on Wednesday. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.06, Zacks reports. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $560.98 million during the quarter, compared to analysts' expectations of $555.14 million. Enovis updated its FY 2025 guidance to 3.100-3.250 EPS.

Enovis Stock Performance

Shares of NYSE:ENOV traded up $0.55 during trading on Friday, reaching $38.67. 1,614,697 shares of the company's stock traded hands, compared to its average volume of 997,556. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The company has a 50 day moving average of $44.72 and a 200-day moving average of $44.27. The stock has a market capitalization of $2.20 billion, a P/E ratio of -17.66 and a beta of 1.94. Enovis has a 12 month low of $37.60 and a 12 month high of $63.96.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC lowered their target price on shares of Enovis from $65.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.